T1	Outcomes 310 316	safety
T2	Outcomes 325 339	immunogenicity
T3	Outcomes 669 675	Safety
T4	Outcomes 719 766	Varicella-zoster virus (VZV) antibody responses
T5	Outcomes 875 922	VZV antibody geometric mean titer (GMT; day 28)
T6	Outcomes 928 980	VZV antibody geometric mean rise (GMR; days 1 to 28)
T7	Outcomes 990 1052	incidence of vaccine-related serious adverse experiences (AEs)
T8	Outcomes 1144 1148	GMTs
T9	Outcomes 1203 1268	estimated GMT ratio (refrigerated formulation/frozen formulation)
T10	Outcomes 1323 1327	GMRs
T11	Outcomes 1369 1396	vaccine-related serious AEs
T12	Outcomes 1436 1451	safety profiles
T13	Outcomes 1500 1533	frequencies of injection-site AEs
T14	Outcomes 1670 1697	frequencies of systemic AEs
T15	Outcomes 1743 1762	vaccine-related AEs
T16	Outcomes 1867 1881	safety profile
T17	Outcomes 1892 1903	immunogenic
